STAT Plus: Pharmalittle: Buttigieg wants pharma to ‘thrive’; U.S. patent panel boosts Biogen, disappoints Gilead
Rise and shine, everyone, another busy day is on the way. We can tell because the short person made another last-minute dash for the local schoolhouse and a parade of vehicles has passed by the placid Pharmalot campus in a hurry. As for us, we are contemplating such frantic paces with a cup of stimulation — peppermint mocha is the choice today. Perhaps this will inspire you to find one of your own. Meanwhile, time to get cracking. Here are a few tidbits to help you on your journey today. Best of luck, and do keep in touch.
Pete Buttigieg has said he wants drug companies to “thrive,” but thriving under a Buttigieg administration will not be business as usual for the pharmaceutical industry, STAT explains. The former mayor of South Bend, Ind., has an expansive platform to lower drug prices that relies on aggressive planks including Medicare negotiation and, if need be, stripping monopolies from companies determined to have priced their drugs abusively.
Continue to STAT Plus to read the full story…
